The LXR inverse agonist SR9238 suppresses fibrosis in a model of non-alcoholic steatohepatitis

Molecular Metabolism

Volumn 4, Issue 4, 2015, Pages 353-357

  Griffett, Kristine ^a   Welch, Ryan D ^a   Flaveny, Colin A ^a   Kolar, Grant R ^a   Neuschwander Tetri, Brent A ^a   Burris, Thomas P ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Fibrosis; Inflammation; Lipogenesis; LXR; NASH

Indexed keywords

LIVER X RECEPTOR AGONIST; SR 9238; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SCREENING; FATTY LIVER; HEPATITIS; IMMUNOHISTOCHEMISTRY; LIPOGENESIS; LIVER FIBROSIS; LIVER PROTECTION; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; WESTERN BLOTTING;

ANIMALIA; MUS; RODENTIA;

EID: 84924281209     PISSN: None     EISSN: 22128778     Source Type: Journal    
DOI: 10.1016/j.molmet.2015.01.009     Document Type: Article

References (20)

1. Ganz M., Szabo G. Immune and inflammatory pathways in NASH. Hepatology International 2013, 7:771-781.
2. Hashimoto E., Taniai M., Tokushige K. Characteristics and diagnosis of NAFLD/NASH. Journal of Gastroenterology and Hepatology 2013, 28(Suppl.4):64-70.
3. Tacke F., Yoneyama H. From NAFLD to NASH to fibrosis to HCC: role of dendritic cell populations in the liver. Hepatology 2013, 58:494-496.
4. Wree A., Broderick L., Canbay A., Hoffman H.M., Feldstein A.E. From NAFLD to NASH to cirrhosis-new insights into disease mechanisms. Nature Reviews Gastroenterology & Hepatology 2013, 10:627-636.
5. Ratziu V. Pharmacological agents for NASH. Nature Reviews Gastroenterology & Hepatology 2013, 10:676-685.
6. Burris T.P., Solt L.A., Wang Y., Crumbley C., Banerjee S., Griffett K., et al. Nuclear receptors and their selective pharmacologic modulators. Pharmacological Reviews 2013, 65:710-778.
7. Savkur R.S., Burris T.P. The coactivator LXXLL nuclear receptor recognition motif. Journal of Peptide Research 2004, 63:207-212.
8. Bensinger S.J., Bradley M.N., Joseph S.B., Zelcer N., Janssen E.M., Hausner M.A., et al. LXR signaling couples sterol metabolism to proliferation in the acquired immune response. Cell 2008, 134:97-111.
9. Ulven S.M., Dalen K.T., Gustafsson J.A., Nebb H.I. LXR is crucial in lipid metabolism. Prostaglandins Leukotrienes and Essential Fatty Acids 2005, 73:59-63.
10. Bennett D.J., Cooke A.J., Edwards A.S. Non-steroidal LXR agonists; an emerging therapeutic strategy for the treatment of atherosclerosis. Recent Patents on Cardiovascular Drug Discovery 2006, 1:21-46.
11. Jaye M. LXR agonists for the treatment of atherosclerosis. Current Opinion in Investigational Drugs 2003, 4:1053-1058.
12. Bradley M.N., Hong C., Chen M., Joseph S.B., Wilpitz D.C., Wang X., et al. Ligand activation of LXR beta reverses atherosclerosis and cellular cholesterol overload in mice lacking LXR alpha and apoE. Journal of Clinical Investigation 2007, 117:2337-2346.
13. Griffett K., Solt L.A., El-Gendy Bel D., Kamenecka T.M., Burris T.P. Aliver-selective LXR inverse agonist that suppresses hepatic steatosis. ACS Chemical Biology 2012, 8:559-567.
14. Trevaskis J.L., Griffin P.S., Wittmer C., Neuschwander-Tetri B.A., Brunt E.M., Dolman C.S., et al. Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice. American Journal of Physiology: Gastrointestinal and Liver Physiology 2012, 302:G762-G772.
15. Zhou J., Febbraio M., Wada T., Zhai Y., Kuruba R., He J., et al. Hepatic fatty acid transporter Cd36 is a common target of LXR, PXR, and PPARgamma in promoting steatosis. Gastroenterology 2008, 134:556-567.
16. Repa J.J., Liang G., Ou J., Bashmakov Y., Lobaccaro J.M., Shimomura I., et al. Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRalpha and LXRbeta. Genes & Development 2000, 14:2819-2830.
17. Sun Y., Hao M., Luo Y., Liang C.P., Silver D.L., Cheng C., et al. Stearoyl-CoA desaturase inhibits ATP-binding cassette transporter A1-mediated cholesterol efflux and modulates membrane domain structure. Journal of Biological Chemistry 2003, 278:5813-5820.
18. Korach-Andre M., Archer A., Barros R.P., Parini P., Gustafsson J.A. Both liver-X receptor (LXR) isoforms control energy expenditure by regulating brown adipose tissue activity. Proceedings of the National Academy of Sciences of the United States of America 2011, 108:403-408.
19. Tosello-Trampont A.C., Landes S.G., Nguyen V., Novobrantseva T.I., Hahn Y.S. Kuppfer cells trigger nonalcoholic steatohepatitis development in diet-induced mouse model through tumor necrosis factor-alpha production. Journal of Biological Chemistry 2012, 287:40161-40172.
20. Zelcer N., Hong C., Boyadjian R., Tontonoz P. LXR regulates cholesterol uptake through Idol-dependent ubiquitination of the LDL receptor. Science 2009, 325:100-104.